HBD3 alters matrix metalloproteinase production in human dendritic cells exposed to Porphyromonas gingivalis hemagglutinin B (HagB)
A study testing dendritic cells exposed to Porphyromonas gingivalis hemagglutinin B (HagB) found that human β-defensin 3 (HBD3) altered HagB-induced matrix metalloproteinase responses in a concentration-dependent manner, enhancing the MMP7 response at low doses while attenuating MMP1, 7, and 9 responses at higher doses, with the authors emphasizing that the predicted signaling pathways underlying this MMP-specific regulation still need to be confirmed using pathway-specific inhibitors.
Dr. Monica Raina
Periodontist
Table of contents
Share
Background & context
Matrix metalloproteinases (MMPs) are zinc- or calcium-dependent enzymes essential to normal extracellular matrix turnover — angiogenesis, bone remodeling, wound healing — but when their activity becomes dysregulated, they instead drive the tissue destruction characteristic of periodontal disease, breaking down the collagen that makes up gingival and periodontal connective tissue and bone matrix.
Building on prior work establishing that human β-defensin 3 (HBD3), a cationic antimicrobial peptide naturally present in the oral cavity, bidirectionally modulates chemokine and cytokine responses of dendritic cells exposed to Porphyromonas gingivalis hemagglutinin B (HagB), an open question remained: does this same defensin also regulate MMP production — the enzymes most directly responsible for periodontal tissue breakdown — or is its effect limited to the chemokine/cytokine response already characterized?
How the question was approached
The prior chemokine/cytokine work had already established that HBD3’s effect on dendritic cell signaling depends on concentration. The natural extension was to ask whether that same concentration-dependent logic extends to a functionally distinct, disease-relevant output: MMP production.
This study addresses that question by layering three levels of analysis onto the existing HagB/HBD3 dendritic cell model:
Establishing the baseline stimulus | Testing concentration-dependent modulation | Mapping the predicted signaling network |
|---|---|---|
Confirming that HagB alone induces a measurable, reproducible MMP response (MMP1, 2, 7, 9, and 12) across three independent dendritic cell preparations, despite differing baseline MMP levels between donors | Testing two HBD3 concentrations (0.2 and 2.0 µM) mixed with HagB to determine whether, as with chemokines/cytokines, low and high HBD3 doses produce opposite effects on specific MMPs | Using a computational dendritic cell signaling model (3,860 species, >15,000 interactions) to predict which pathways (MyD88/TRAF6, SHC1/ERK, converging on NFKB, AP1, SP1, NFAT, CTNNB1, HIF1A) drive HagB-induced MMP transcription, and how HBD3 might interrupt them |
This approach extends the established concentration-dependent framework from cytokines/chemokines into a second, mechanistically distinct functional readout — testing whether the same regulatory logic generalizes to the proteinases most directly implicated in periodontal tissue destruction.
What the results show at different levels
For the specific MMP responses: The effect of HBD3 was not uniform across all five MMPs — low-dose HBD3 (0.2 µM) significantly enhanced the HagB-induced MMP7 response, while high-dose HBD3 (2.0 µM) significantly attenuated MMP1, 7, and 9 responses, and MMP2 and MMP12 were unaffected at either concentration, indicating that HBD3’s regulatory effect is both concentration- and MMP-specific rather than a uniform global suppression or enhancement.
For consistency with the chemokine/cytokine findings: The directional pattern — low HBD3 enhancing, high HBD3 attenuating a HagB-induced response — mirrors what was previously observed for chemokines and cytokines, suggesting HBD3 may operate through a shared concentration-dependent regulatory mechanism across multiple classes of inflammatory mediators rather than a mechanism specific to one biomarker family.
For periodontal disease relevance: Because elevated MMP activity is directly implicated in the connective tissue and bone destruction of periodontitis, a host peptide capable of attenuating select HagB-induced MMP responses (MMP1, 7, 9) at higher concentrations represents a candidate mechanism by which the host’s own innate immune peptides might modulate — rather than simply trigger — antigen-driven tissue damage.
The open challenge
The predicted signaling network offers plausible explanations for the observed MMP-specific patterns — for example, that MAPK-driven pathways may simultaneously activate and inhibit MMP2 and MMP13 expression through opposing transcription factors, potentially explaining why those two MMPs showed no net change — but these mechanistic links remain computational predictions. Confirming them, and determining how much CD14 inhibition by HBD3 actually accounts for the attenuated MMP responses, will require direct testing with pathway-specific inhibitors.
Going forward
Future work needs to validate the predicted MyD88/TRIF and MAPK-dependent pathways experimentally, determine whether this same HBD3-mediated MMP regulation occurs in the other cell types known to produce MMPs in periodontal tissue (gingival epithelial cells, fibroblasts, macrophages, PMN leukocytes), and clarify how concentration-dependent shifts in host defensin activity might be leveraged therapeutically to arrest or attenuate the progression of periodontal tissue damage.
